US92532F1003 - Common Stock
These healthcare giants have plenty of room left to run.
These companies have the therapies to boost revenue for a decade.
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.
Fast-growing, underappreciated stocks to buy are trading at a steep discount and will reward investors as they rise in value.
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.
BP and Chinese search leader Baidu lead this weekend's watch list.
Their products will enjoy strong demand regardless of what happens with the economy.
It's still a great time to be a long-term investor.
The healthcare industry isn't going anywhere.
On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before.
These companies have what it takes to drive long-term share performance.
Putting together your watch list? Look for stocks with an 80-plus RS Rating. Vertex Pharmaceuticals stock meets that criteria, rising to 84.
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.
Vertex shares are extending last year's gains, and that trend probably isn't over.
All three are protected by sales of in-demand products, with more on the way.
These companies are set for a new era of growth.
Bargains can easily be found as the new year gets underway.
Vertex is heading for a new phase of growth.
These stocks all dropped in the double digits last year. But their future prospects are brilliant.
Expect these stocks to boost your portfolio in the long run.
This space is rife with opportunity for investors.
This company's long-term thesis looks impeccable.
These stocks could be huge winners for patient investors.
A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?
These healthcare companies' revenue and earnings have grown, and they expect more growth.
These healthcare stocks have a lot going for them in the new year.
These stocks have been solid performers despite the macroeconomic uncertainties in 2022.
Regularly investing in both up and down markets can help you build a resilient portfolio over time.
Don't let your retirement planning fall by the wayside in the current market.
The current market is still full of wonderful opportunities for investors of all trading styles.
The healthcare industry presents opportunities for both growth and value investors.